



Mads Lause Mogensen M.Sc., Ph.D. Chief Executive Officer (CEO) in mm@treatsystems.com







Treat Systems is part of the Judex/Amphi family



- HIGH PERFORMANCE TEAM

Treat Systems is a dynamic and innovative Danish SMV focused on developing certified healthcare software solutions including decision support, machine learning (ML) and artificial intelligence (AI). Our key clinical focus areas are within infectious diseases, microbiology, antibiotic therapy and antibiotic resistance.

- Decision support
- Physiological models
- •Machine learning
- •Scientific connections to Universities
- Cost-benefit analysis
- Artificial intelligence
- •Causal probabilistic (Bayesian) networks

Modelling

Infectious diseases

- Workflow analysis
- Microbiological and pathological understanding
- Clinical Trails
- Antimicrobial Stewardship
- Sepsis
- •Infection control and surveillance

Clinical understanding ISO 13485 – Quality Management System
ISO 62304 – Software life-cycle

processes

- •ISO 14971 Risk Management
- •ISO 27001 Information security
- •ISO 27701 Privacy
- ISO 62366 Usability
- •ISO 14155 Clinical Investigation


Regulatory compliance

Multi language programming (C#, Angular, C++, JAVA, VBA)
Web based technologies
SQL or InterSystems Caché database structure
Integration to hospital systems e.g. HL7 or FHIR
Statistical analysis (SPSS, R, Excel, Matlab)

Technologies


KEY TECHNOLOGIES

WE HAVE FALLEN IN LOVE WITH BAYESIAN NETWORKS AND COST-BENEFIT



TRADEOFF BETWEEN PERFORMANCE AND TRANSPARENCY

The disadvantage of advanced AI models is that it can be difficult for humans to see how the model has arrived at a given outcome.



interpretation of the algorithm's results

Rapid identification and appropriate antibiotic treatment is the single most important intervention in treating sepsis Surviva.

- Subtle signs and symptoms
- Don't wait until the patient is hypotensive!
- Scores are a common feature in sepsis assessment
 - gSOFA/SOFA are part of the latest definitions



Many publications of ML scores for early identification/severity assessment

AIM: With electronic prehospital medical records, can riskstratification start prior to ED arrival? Can existing scores be used and can we do better with ML?

*this presentation contains minor deviations from numbers presented in the abstract due to additional data made available on hospital admissions after submission

COLLECTING CLINICAL DATA

- USE WHAT IS ALREADY AVAILABLE

- All ambulances in Denmark are equipped with devices to collect data in an electronic prehospital medical record (amPHI) which is automatically shared with the emergency department at the arrival hospital
 - Many clinical patient parameters are collected and documented automatically e.g. Blood pressure, pulse, blood saturation and ECG very different from hospital environment
 - For some critical patients <10% end tidal CO2 (ETCO2) and respiratory frequency (RF) are measured automatically</p>
 - Electronic prehospital records present an opportunity to use this data for decision support potential to guide diagnostic testing (e.g. POCT), early treatment or interventions





OUR STUDY -METHODS

Patients

PMR data collected from Danish Regions for all prehospital journeys between 1 July 2016 and 31 December 2020.

Data collected

All physiological variables (temperature, HR, systolic/diastolic BP, respiratory rate, O2 saturation, GCS and blood glucose).

Outcomes

Positive blood culture, 30-day mortality and ICU admission

Comparators

Standard vital-sign-based clinical triage scores – qSOFA, DEPT (Danish Emergency Process Triage), NEWS2, RETTS

Data preparation

After cleaning and arranging the data (combining variables, converting to timeslices), data were split into training (2017-2019) and test (2020) sets

MACHINE LEARNING (ML) MODEL DEVELOPMENT


-BASIC MODEL DEVELOPMENT STEPS

Using training data


- Exploratory data analysis investigate links between variables and to outcomes
- Feature engineering identify new features (combinations/transformations)
- Feature selection
- Model selection tuning/optimization of model parameters

Using test data


 Model assessment – visualization and interpretation of the results



INCLUSION/EXCLUSION



AGE DISTRIBUTION




DESCRIPTIVE STATISTICS - PHYSIOLOGICAL MEASUREMENTS

	Journals with measurement, n (%)	Measurements, n	Frequency, median [IQR]	Distribution, median [IQR]		
HR	214941 (92.3)	2421800	9.0 [6.0-14.0]	84.0 [71.0-99.0]		
SpO2	212723 (91.3)	2181696	8.0 [5.0-12.0]	96.0 [94.0-98.0]		
DBP	207563 (89.1)	724691	3.0 [2.0-4.0]	77.0 [66.0-89.0]		
SBP	207447 (89.0)	724180	3.0 [2.0-4.0]	136.0 [118.0-156.0]		
MAP	203321 (87.3)	630716	3.0 [2.0-4.0]	97.0 [84.3-110.7]		n (%
RR	198994 (85.4)	570435	2.0 [1.0-3.0]	18.0 [16.0-22.0]	Sinus	75294 (64.2
GCS	205415 (88.2)	450461	2.0 [1.0-3.0]	15.0 [15.0-15.0]	Sinus tachycardia	
HeartRhythm	80201 (34.4)	117311	1.0 [1.0-2.0]	NaN	Atrial fibrillation Block configuration	
etCO2	10365 (4.4)	114977	9.0 [6.0-13.0]	4.3 [3.3-5.2]	Pacer rhythm	2011 (1.7
Pain (VAS)	60844 (26.1)	114625	1.0 [1.0-2.0]	3.0 [0.0-6.0]	Ischemia/infarction Bradycardia	1853 (1.6 1799 (1.5
Temperature	96734 (41.5)	108268	1.0 [1.0-1.0]	36.8 [36.6-37.6]	Asystole	1140 (1.0
Glucose	57496 (24.7)	66839	1.0 [1.0-1.0]	6.8 [5.6-8.7]	Unknown/Error Pea	347 (0.3 232 (0.2
SpCO	319 (0.1)	486	1.0 [1.0-2.0]	96.0 [92.0-98.0]	Vt	
SpMet	16 (0.0)	20	1.0 [1.0-1.2]	37.0 [36.0-91.5]	Vf	
					Broad tachycardia	150 (0.1


DEMOGRAPHICS, OUTCOMES BY 112 STATUS

	Call112group	no	yes	All
Journals		102462	131706	234168
Mortality				
M30, n (%)		11717 (11.4%)	7733 (5.9%)	19450 (8.3%)
Blood cultures				
BC taken, n (%)		30186 (29.5%)	20086 (15.3%)	50272 (21.5%)
BC+, n (%)		2609.0 (8.6%)	1543.0 (7.7%)	4152.0 (8.3%)
Admission link, n (%)		90642 (88.5%)	117613 (89.3%)	208255 (88.9%)
First department				
Emergency/Acute		67466 (74.4%)	106680 (90.7%)	174146 (83.6%)
Medical		18610 (20.5%)	7324 (6.2%)	25934 (12.5%)
Surgical		2791 (3.1%)	125 (0.1%)	2916 (1.4%)
Pediatrics		771 (0.9%)	3107 (2.6%)	3878 (1.9%)
Other		1004 (1.1%)	377 (0.3%)	1381 (0.7%)
Length of stay				
<1 day, n (%)		30246 (33.4%)	73456 (62.5%)	103702 (49.8%)
1-5 days, n (%)		34608 (38.2%)	28968 (24.6%)	63576 (30.5%)
5-10 days, n (%)		15612 (17.2%)	9087 (7.7%)	24699 (11.9%)
10+ days, n (%)		10177 (11.2%)	6102 (5.2%)	16279 (7.8%)
ICU				
ICU admission, n (%)		2010.0 (2.2%)	3425.0 (2.9%)	5435.0 (2.6%)


FACTORS INFLUENCING PATIENT OUTCOMES - CHARLSON



MORTALITY BY ICD10 CODE GROUP




SURVIVAL CURVES, STRATIFIED BY NUMBER OF VISITS IN THE LAST 365 DAYS




RESULTS AND PERFORMANCE

- A MORE PRECISE ESTIMATE OF THE SEVERITY OF THE PATIENTS CAN BE FOUND VIA ADVANCED DECISION SUPPORT



RESULTS AND PERFORMANCE – 30-DAY MORTALITY


- TO UTILIZE THE IMPROVED PREDICTIONS, OPERATING POINTS MUST BE CHOSEN TO GUIDE INTERVENTION VIA ADVANCED DECISION SUPPORT



RESULTS AND PERFORMANCE – **30**-DAY **M**ORTALITY


- TO UTILIZE THE IMPROVED PREDICTIONS, OPERATING POINTS MUST BE CHOSEN TO GUIDE INTERVENTION VIA ADVANCED DECISION SUPPORT

Although ML models perform significantly better than the baseline models there is no magic-bullet cut-off with high sensitivity AND high specificity, PPV.



APPLICATIONS/FUTURE WORK

- DECISION SUPPORT UNIFIES PERSONALIZED MEDICINE, MACHINE LEARNING, ARTIFICIAL INTELLIGENCE AND CLINICAL PRACTICE



Data is collected and is already collected in the ambulances


... why not use this gold mine to automate the clinical workflow using decision support?


The ML models perform significantly better than the baseline models (clinical practice)

... However, precision remains low with large numbers of false positives

Potential benefits from use of ML in prehospital risk, but further investigation required

... e.g. prospective trial of additional POC test for high risk/safety of low-risk patients






How to take the artificial out of <u>A</u>I


White box and explanatory decision support

How do we get things done




CAUSAL PROBABILISTIC NETWORK (BAYSIAN NETWORKS)

THE BEAUTY OF CAUSALITY



CAUSAL PROBABILISTIC NETWORK (BAYSIAN NETWORKS)


THE BEAUTY OF CAUSALITY



CAUSAL PROBABILISTIC NETWORK (BAYSIAN NETWORKS)

THE BEAUTY OF CAUSALITY

Advanced example



Simple example

